CPI 613

Drug Profile

CPI 613

Alternative Names: Bylantra; CPI-613

Latest Information Update: 31 Mar 2017

Price : $50

At a glance

  • Originator Cornerstone Pharmaceuticals; Stony Brook University
  • Developer Cornerstone Pharmaceuticals; National Cancer Institute (USA); Wake Forest University School of Medicine
  • Class Antineoplastics; Carboxylic acids; Coenzymes; Fatty acids; Small molecules; Thiophenes
  • Mechanism of Action Ketoglutarate dehydrogenase complex inhibitors; Pyruvate dehydrogenase complex inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Myelodysplastic syndromes; Acute myeloid leukaemia; Pancreatic cancer
  • New Molecular Entity Yes

Highest Development Phases

  • Phase II Myelodysplastic syndromes; Pancreatic cancer; Small cell lung cancer; Solid tumours
  • Phase I/II Cancer
  • Phase I Acute myeloid leukaemia; Biliary cancer; Colorectal cancer; Haematological malignancies; Hodgkin's disease; Non-Hodgkin's lymphoma

Most Recent Events

  • 31 Mar 2017 Cornerstone Pharmaceutical terminates a phase I/II trial in Pancreatic cancer (Combination therapy) in USA (NCT00907166)
  • 23 Mar 2017 The US FDA grants approval to initiate pivotal clinical trials for CPI-613 in Acute myeloid leukaemia and Pancreatic Cancer
  • 23 Mar 2017 Cornerstone Pharmaceuticals plans pivotal trials for Acute myeloid leukaemia and Pancreatic cancer
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top